Antiangiogenic effects of anti–tumor necrosis factor α therapy with infliximab in psoriatic arthritis
Version of Record online: 6 MAY 2004
Copyright © 2004 by the American College of Rheumatology
Arthritis & Rheumatism
Volume 50, Issue 5, pages 1636–1641, May 2004
How to Cite
Cañete, J. D., Pablos, J. L., Sanmartí, R., Mallofré, C., Marsal, S., Maymó´, J., Gratacós, J., Mezquita, J., Mezquita, C. and Cid, M. C. (2004), Antiangiogenic effects of anti–tumor necrosis factor α therapy with infliximab in psoriatic arthritis. Arthritis & Rheumatism, 50: 1636–1641. doi: 10.1002/art.20181
- Issue online: 6 MAY 2004
- Version of Record online: 6 MAY 2004
- Manuscript Accepted: 16 JAN 2004
- Manuscript Received: 25 SEP 2003
- Fondo de Investigaciones Sanitarias. Grant Numbers: 1548/01, G03/152
- Institut d'Investigacións Biomèdiques Agustí Pí i Suñer (IDIBAPS)
Neovascularization, with an increased number of synovial vessels with a characteristic morphology, seems to contribute to the progression of psoriatic arthritis (PsA). Accordingly, angiogenesis may be an important therapeutic target in PsA. The aim of this study was to analyze the effects of infliximab on angiogenesis in the synovial membrane of patients with PsA who responded to this therapy.
The study group comprised 9 patients with PsA who were selected for the presence of active polyarthritis (including knee synovitis) despite methotrexate therapy. Clinical and biologic evaluations were performed at each visit. Arthroscopy and synovial biopsies were performed at week 0, before infliximab therapy was initiated, and at week 8, after administration of 3 intravenous infusions of infliximab (5 mg/kg). We used immunohistochemistry to identify changes in infiltrating cells and in the angiogenesis modulators αvβ3 integrin, vascular endothelial growth factor (VEGF), angiopoietin 2 (Ang-2), flt-1 (VEGF receptor 1 [VEGFR-1]), kinase insert domain receptor [KDR]/flk-1 (VEGFR-2), and stromal cell–derived factor 1 (SDF-1). Neovascularization was assessed by automated histomorphometry of CD31+ vessels and by measuring αvβ3 expression.
Rapid and significant clinical and biological improvement were observed after treatment in all patients. In the synovium, infliximab therapy induced a significant reduction in macrophages, the CD31+ vascular area, αvβ3+ neovessels/Ulex europaeus agglutinin+ vessels, VEGF and its receptor KDR/flk-1 (VEGFR-2), and SDF-1+ vessels. Expression of flt-1 (VEGFR-1), and SDF-1 in lining cells showed a nonsignificant reduction, whereas expression of Ang-2 increased. In 3 patients, reverse transcription–polymerase chain reaction confirmed the changes in some of these markers at the messenger RNA level.
These results show consistent changes in several factors involved in angiogenesis regulation, in parallel with the clinical response to infliximab in patients with PsA. The pattern of reduced VEGF with increased Ang-2 suggests vascular regression as a potential mechanism underlying the antiangiogenic effect of infliximab.